| Symbol
| FOXO1
| contributors: mct - updated : 17-08-2020
|
| HGNC name
| forkhead box O1
|
| HGNC id
| 3819
|
| corresponding disease(s)
|
ARMS
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
| fusion
|
|
| protein chimeric
| |
fused to PAX3 in alveolar rhabdomyosarcoma with translocation t(2;13)(q35;q14) and to PAX7 with translocation t(1;13)(p36;q14) (see BARMS1, BARMS2, BARMS13) | | constitutional
|
|
| --over
|
| |
early in the decidualization process | | constitutional
|
|
|
| loss of function
|
can improve hepatic metabolism during insulin resistance and the metabolic syndrome  | | constitutional
|
|
|
|
| |
silencing FOXO1 decreases the expression of RUNX2 and impairs bone formation | | tumoral
|
|
|
|
| |
enhanced prostate cancer cell migration in a RUNX2-dependent manner | |
| Susceptibility
|
to type 2 diabetes (minor contributor) to keratoconus |
| Variant & Polymorphism
SNP
| haplotype 3 'TCA' have higher HbA1c levels and a 1.14-fold higher all-cause mortality risk, attributable to death from diabetes, for which a 2.43-fold increase was observed |
|
SNP rs2721068 was significantly associated with type 2 diabetes |
|
rs2721051 near FOXO1 strongly associated to keratoconus |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | muscle | | |
| partial inhibition of hepatic Foxo1 might be a good target to prevent the progression of a vicious cycle that causes metabolic disease |
| | | |
|
| FoxO1-deficient embryos manifest progressive apoptotic cell death | |
mice lacking FOXO1 in steroidogenic factor 1 (NR5A1) neurons of the ventromedial hypothalamus are lean due to increased energy expenditure |
|
mice with Treg-cell-specific deletion of Foxo1 develop a fatal inflammatory disorder similar in severity to that seen in Foxp3-deficient mice, but without the loss of Treg cells |